NCT04059978 (CANAB II) is a NA clinical trial of CBD in Acute Nociceptive Pain, sponsored by University Hospital, Basel, Switzerland.

Who is sponsoring NCT04059978?

NCT04059978 is sponsored by University Hospital, Basel, Switzerland.

What drugs are being tested in NCT04059978?

Interventions in NCT04059978: CBD, Placebo, Remifentanil.

What condition does NCT04059978 study?

NCT04059978 studies Acute Nociceptive Pain, Hyperalgesia, Allodynia, Opioid-induced Hyperalgesia.

Is NCT04059978 still recruiting?

NCT04059978 is currently completed. Last updated 19 October 2020.

Last reviewed 2020-10-19 · How we verify

NCT04059978: CANAB II

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pain Response to Cannabidiol in Opioid-induced Hyperalgesia, Acute Nociceptive Pain and Allodynia By Using a Model Mimicking Acute Pain in Healthy Adults

Completed NA Last updated 19 October 2020

What this trial tests

NA trial testing CBD in Acute Nociceptive Pain in 21 participants. Completed in 15 October 2020.

Timeline

26 May 2020

Primary endpoint
15 October 2020

15 October 2020

Quick facts

Lead sponsor	University Hospital, Basel, Switzerland
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	basic science
Enrollment	21
Start date	26 May 2020
Primary completion	15 October 2020
Estimated completion	15 October 2020
Sites	1 location across Switzerland

Drugs / interventions tested

CBD — full drug profile →
Placebo
Remifentanil — full drug profile →

Conditions studied

Acute Nociceptive Pain — all drugs for Acute Nociceptive Pain →
Hyperalgesia — all drugs for Hyperalgesia →
Allodynia — all drugs for Allodynia →
Opioid-induced Hyperalgesia — all drugs for Opioid-induced Hyperalgesia →

Sponsor

University Hospital, Basel, Switzerland

Who can join

18 and older, any sex, with Acute Nociceptive Pain or Hyperalgesia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective, randomized, placebo-controlled, double-blinded, crossover study to investigate the effect of cannabidiol (CBD) on remifentanil-induced hyperalgesia in healthy volunteers in a well-established acute pain model. Participants are randomized according to the order of the two treatments (CBD + Remifentanil or Placebo + Remifentanil).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Pain response to cannabidiol in opioid-induced hyperalgesia, acute nociceptive pain, and allodynia using a model mimicking acute pain in healthy adults in a randomized trial (CANAB II).
Dieterle M, Zurbriggen L, Mauermann E, Mercer-Chalmers-Bender K, et al · · 2022 · cited 20× · PMID 35239547 · DOI 10.1097/j.pain.0000000000002591
Exploring the therapeutic potential of cannabidiol in soft tissue wound healing: Delivery strategies and anti-inflammatory pathways.
Dubnika A, Jurgelane I, Grava-Ceplite A, Tornaci S, et al · · 2026 · cited 1× · PMID 42039297 · DOI 10.1016/j.apsb.2025.10.001

Verify or expand the search:

Other trials of CBD

Trials testing the same drug.

NCT05067387 — Evaluation of Oral THC and CBD in Men and Women · Phase 1 · not yet recruiting
NCT06878417 — Cannabinoids for Osteoarthritis Pain Effectiveness Trial · NA · recruiting
NCT06014424 — Cannabidiol Medication Intervention Trial · Phase 2 · recruiting
NCT05514899 — Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV · Phase 2 · recruiting
NCT05317013 — CBD in Postmenopausal Women With Osteopenia · Phase 1 · terminated

Other University Hospital, Basel, Switzerland trials

Trials by the same sponsor.

NCT07444788 — Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants · Phase 1 · recruiting
NCT07494214 — Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants · Phase 1 · recruiting
NCT07419048 — Artificial Intelligence or Human Hand? Evaluating Inferior Vena Cava Imaging for Hydration Status · recruiting
NCT06978777 — Effect of Caffeine on Cold-stimulated Brown Adipose Tissue Activity · NA · recruiting
NCT07273630 — Effect of Protein Supplementation and Fluid Restriction on Plasma Sodium Levels in Patients Undergoing Pituitary Surgery · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04059978 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Basel, Switzerland
Last refreshed: 19 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04059978.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing